BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28548124)

  • 1. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
    Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
    Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia.
    Chapman J; Geyer JT; Khanlari M; Moul A; Casas C; Connor ST; Fan YS; Watts JM; Swords RT; Vega F; Orazi A
    Mod Pathol; 2018 Mar; 31(3):429-441. PubMed ID: 29192651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
    Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
    Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia.
    Courville EL; Wu Y; Kourda J; Roth CG; Brockmann J; Muzikansky A; Fathi AT; de Leval L; Orazi A; Hasserjian RP
    Mod Pathol; 2013 Jun; 26(6):751-61. PubMed ID: 23307061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
    Calvo X; Garcia-Gisbert N; Parraga I; Gibert J; Florensa L; Andrade-Campos M; Merchan B; Garcia-Avila S; Montesdeoca S; Fernández-Rodríguez C; Salido M; Puiggros A; Espinet B; Colomo L; Roman-Bravo D; Bellosillo B; Ferrer A; Arenillas L
    Blood Adv; 2020 Oct; 4(20):5285-5296. PubMed ID: 33108455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.
    Gelsi-Boyer V; Cervera N; Bertucci F; Brecqueville M; Finetti P; Murati A; Arnoulet C; Mozziconacci MJ; Mills KI; Cross NC; Vey N; Birnbaum D
    Haematologica; 2013 Apr; 98(4):576-83. PubMed ID: 23065512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
    Hwang SM; Kim SM; Nam Y; Kim J; Kim S; Ahn YO; Park Y; Yoon SS; Shin S; Kwon S; Lee DS
    Leuk Res; 2019 Sep; 84():106190. PubMed ID: 31377458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia.
    Patnaik MM; Lasho TL; Vijayvargiya P; Finke CM; Hanson CA; Ketterling RP; Gangat N; Tefferi A
    Blood Cancer J; 2016 Jan; 6(1):e385. PubMed ID: 26771811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How I investigate chronic myelomonocytic leukemia.
    Sangiorgio VFI; Arber DA; Orazi A
    Int J Lab Hematol; 2020 Apr; 42(2):101-108. PubMed ID: 31841277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Srsf2
    Xu JJ; Chalk AM; Wall M; Langdon WY; Smeets MF; Walkley CR
    Leukemia; 2022 Dec; 36(12):2883-2893. PubMed ID: 36271153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
    Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
    Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
    Jian J; Qiao Y; Li Y; Guo Y; Ma H; Liu B
    Clin Transl Oncol; 2021 Sep; 23(9):1731-1742. PubMed ID: 33861431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
    Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M; Robertson KD; Bosi A; Droin N; Vannucchi AM; Tefferi A; Hunter A; Padron E; Solary E; Patnaik MM
    Leukemia; 2020 May; 34(5):1407-1421. PubMed ID: 31836856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-hit TET2 mutations as a differential molecular signature of oligomonocytic and overt chronic myelomonocytic leukemia.
    Garcia-Gisbert N; Arenillas L; Roman-Bravo D; Rodriguez-Sevilla JJ; Fernández-Rodríguez C; Garcia-Avila S; Velez P; Gibert J; Fernández-Ibarrondo L; Salar A; Florensa L; Bellosillo B; Ferrer A; Calvo X
    Leukemia; 2022 Dec; 36(12):2922-2926. PubMed ID: 36273104
    [No Abstract]   [Full Text] [Related]  

  • 15. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
    Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of targeted sequencing and flow cytometry to identify patients with a clinically significant monocytosis.
    Cargo C; Cullen M; Taylor J; Short M; Glover P; Van Hoppe S; Smith A; Evans P; Crouch S
    Blood; 2019 Mar; 133(12):1325-1334. PubMed ID: 30606702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.
    Kohlmann A; Grossmann V; Klein HU; Schindela S; Weiss T; Kazak B; Dicker F; Schnittger S; Dugas M; Kern W; Haferlach C; Haferlach T
    J Clin Oncol; 2010 Aug; 28(24):3858-65. PubMed ID: 20644105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia.
    Federmann B; Abele M; Rosero Cuesta DS; Vogel W; Boiocchi L; Kanz L; Quintanilla-Martinez L; Orazi A; Bonzheim I; Fend F
    Hum Pathol; 2014 Dec; 45(12):2471-9. PubMed ID: 25305095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia.
    Ball M; List AF; Padron E
    Blood; 2016 Nov; 128(20):2381-2387. PubMed ID: 27707735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.